Could a diabetes drug reverse liver scarring?
NCT ID NCT06005012
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether semaglutide, a drug already used for obesity and type 2 diabetes, can reduce liver scarring in people with non-alcoholic fatty liver disease (NAFLD). Participants are adults aged 40 to 80 who are overweight or have type 2 diabetes. The trial will also validate a screening method to identify those at high risk for advanced liver disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- semaglutide, a GLP-1 receptor agonist drug approved for obesity and type 2 diabetes
- What this could lead to
- If successful, this could provide a treatment option for liver scarring in people with fatty liver disease, potentially preventing progression to cirrhosis.
- What could go wrong
- This is a phase 2 trial with 120 participants, so results are preliminary. Semaglutide may not reduce fibrosis in all patients, and side effects like nausea or gastrointestinal issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FIBROSIS, LIVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Diego
La Jolla, California, 92093, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a scan replace the needle? ultrasound and MRI put to the test against liver biopsy for fatty liver disease
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?
- A daily pill for obesity? zenagamtide faces its biggest test yet.